- Associated Press•2 months ago
On a per-share basis, the South San Francisco, California-based company said it had a loss of 42 cents. The biopharmaceutical company posted revenue of $109,000 in the period. The company's shares closed ...
- Zacks•last year
Targacept, Inc. announced disappointing top-line data from a phase I/II exploratory study on its candidate TC-6499 for the treatment of diabetic gastroparesis.
Targacept, Inc. (TRGT)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
As of 3:59 PM EDT. Market open.
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|